表紙
市場調查報告書

口腔粘膜炎 : 開發中產品分析

Oral Mucositis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 192750
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
口腔粘膜炎 : 開發中產品分析 Oral Mucositis - Pipeline Review, H2 2019
出版日期: 2019年12月02日內容資訊: 英文 126 Pages
簡介

口腔黏膜炎是最常見的黏膜炎之一,是在癌症外手術、化療、放射線療法時經常併發的衰弱性疾病。主要的症狀有口腔內部色調異常或唾液分泌減少、黏膜構造發生變化、唇、舌浮腫等。主要治療方法有清潔口腔(口腔衛生)、口腔內部的清創手術等。

本報告提供全球各國治療口腔粘膜炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

口腔粘膜炎概要

治療藥的開發

  • 口腔粘膜炎開發中產品:概要
  • 口腔粘膜炎開發中產品:比較分析

各企業開發中的口腔粘膜炎治療藥

大學/研究機關研究中的口腔粘膜炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

口腔粘膜炎治療藥:開發中的產品一覽(各企業)

口腔粘膜炎治療藥:研究中的產品一覽(各大學/研究機關)

口腔粘膜炎開發治療藥的企業

  • Aldeyra Therapeutics, Inc.
  • Cellceutix Corporation
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical Co., Ltd.
  • Galera Therapeutics, Inc.
  • Onxeo SA
  • Oragenics, Inc.
  • 大塚集團
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spherium Biomed S.L.

口腔粘膜炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

口腔粘膜炎治療藥:暫停開發的產品

口腔粘膜炎治療藥:中止開發的產品

口腔粘膜炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11572IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H2 2019, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 10, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Oral Mucositis - Overview
  • Oral Mucositis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Oral Mucositis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Oral Mucositis - Companies Involved in Therapeutics Development
  • Alivio Therapeutics Inc
  • Allander Biotechnologies LLC
  • BIOCND Inc
  • Clevexel Pharma SAS
  • Enzychem Lifesciences Corp
  • Galera Therapeutics Inc
  • Genekey Biotech Chengdu Co Ltd
  • GlycoMira Therapeutics Inc
  • Humanetics Corp
  • Innovation Pharmaceuticals Inc
  • Lakewood-Amedex Inc
  • Matrix Biomed Inc
  • Monopar Therapeutics Inc
  • Oragenics Inc
  • Soligenix Inc
  • Spectrum Pharmaceuticals Inc
  • Spherium Biomed SL
  • Sunny Pharmtech Inc
  • Oral Mucositis - Drug Profiles
  • AG-013 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avasopasem manganese - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BCD-600 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brilacidin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • clonidine ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CVXL-0095 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dusquetide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • genistein - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-0111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • levoleucovorin calcium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lidocaine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mosedipimod - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nu-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • phenylbutyrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pralatrexate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Agonize KGFR for Chemotherapy Induced Gastrointestinal Mucositis and Oral Mucositis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tempol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oral Mucositis - Dormant Projects
  • Oral Mucositis - Discontinued Products
  • Oral Mucositis - Product Development Milestones
  • Featured News & Press Releases
  • Nov 25, 2019: Innovation Pharmaceuticals and FDA agree to waive initial pediatric study plan requirement regarding brilacidin for the prevention of oral mucositis
  • Nov 13, 2019: Innovation Pharmaceuticals: Oral Cancer on the Rise; company offers perspectives on opportunity of Brilacidin for the prevention of Oral Mucositis
  • Oct 08, 2019: Innovation Pharmaceuticals cites recent academic literature showing host defense proteins at Cutting-Edge of Medicine for Multiple Diseases
  • Oct 08, 2019: Galera Therapeutics announces two-year tumor outcomes data for GC4419
  • Oct 03, 2019: Soligenixs SGX942 on track to fill unmet medical need; targeting oral mucositis in patients with head and neck cancer
  • Sep 30, 2019: Oragenics presents interim data on the AG013 phase 2 clinical trial at the European Society for Medical Oncology Congress 2019
  • Sep 25, 2019: Oragenics announces phase 2 clinical trial of AG013 reaches enrollment of 158 patients
  • Sep 23, 2019: Oragenics to present interim data on AG013 at the European Society of Medical Oncology Congress
  • Aug 28, 2019: Soligenix announces positive recommendation by Independent Data Monitoring Committee on its phase 3 clinical trial of SGX942 for the treatment of oral mucositis in Head and Neck Cancer
  • Aug 15, 2019: Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications
  • May 29, 2019: Innovation Pharmaceuticals provides update on brilacidin at 2019 BIO International Convention
  • May 20, 2019: Oragenics provides development update of AG013 for oral mucositis
  • May 01, 2019: Innovation Pharmaceuticals receives FDA End-of-Phase 2 meeting minutes
  • Apr 23, 2019: Innovation Pharmaceuticals - JAMA Article reinforces need for novel oral mucositis treatments in supportive cancer care
  • Apr 09, 2019: Innovation Pharmaceuticals reports enhancements in manufacture of Brilacidin phase 3 drug supply
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Oral Mucositis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Oral Mucositis - Pipeline by Alivio Therapeutics Inc, H2 2019
  • Oral Mucositis - Pipeline by Allander Biotechnologies LLC, H2 2019
  • Oral Mucositis - Pipeline by BIOCND Inc, H2 2019
  • Oral Mucositis - Pipeline by Clevexel Pharma SAS, H2 2019
  • Oral Mucositis - Pipeline by Enzychem Lifesciences Corp, H2 2019
  • Oral Mucositis - Pipeline by Galera Therapeutics Inc, H2 2019
  • Oral Mucositis - Pipeline by Genekey Biotech Chengdu Co Ltd, H2 2019
  • Oral Mucositis - Pipeline by GlycoMira Therapeutics Inc, H2 2019
  • Oral Mucositis - Pipeline by Humanetics Corp, H2 2019
  • Oral Mucositis - Pipeline by Innovation Pharmaceuticals Inc, H2 2019
  • Oral Mucositis - Pipeline by Lakewood-Amedex Inc, H2 2019
  • Oral Mucositis - Pipeline by Matrix Biomed Inc, H2 2019
  • Oral Mucositis - Pipeline by Monopar Therapeutics Inc, H2 2019
  • Oral Mucositis - Pipeline by Oragenics Inc, H2 2019
  • Oral Mucositis - Pipeline by Soligenix Inc, H2 2019
  • Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2019
  • Oral Mucositis - Pipeline by Spherium Biomed SL, H2 2019
  • Oral Mucositis - Pipeline by Sunny Pharmtech Inc, H2 2019
  • Oral Mucositis - Dormant Projects, H2 2019
  • Oral Mucositis - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Oral Mucositis - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Oral Mucositis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top